receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds to the human α_{1d} adrenergic receptor with a binding affinity which is at least 25-fold higher than the binding affinity with which the compound binds to (i) a human α_{1a} adrenergic receptor and (ii) a human α_{1b} adrenergic receptor, and the compound binds to the human α_{1d} adrenergic receptor with a binding affinity which is at least ten-fold higher than the binding affinity with which the compound binds to a human 5-HT_{1a} receptor.--

B' cancel.

--7. (Amended) A method of inhibiting activation of a human α_{1d} adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound has the structure:

B2



wherein each m and n is independently an integer from 0 to 2;

wherein each Y and Z is independently



wherein R_1 and R_2 (i) are independently H, branched or unbranched C_1-C_6 alkyl or alkoxy, branched or unbranched C_2-C_6 alkenyl or alkynyl, branched or unbranched C_1-C_6 hydroxyalkyl, hydroxy, substituted or unsubstituted aryl or aryl-(C_1-C_6)-

alkyl, or substituted or unsubstituted heteroaryl or heteroaryl-(C_1-C_6)-alkyl, wherein the substituent if present is a halogen, CN, nitro, hydroxy, branched or unbranched C_1-C_6 alkyl or alkoxy group, or branched or unbranched C_2-C_6 alkenyl or alkynyl group; or (ii) taken together form a substituted or unsubstituted cycloalkyl ring containing 3-10 carbons, wherein the substituent if present is a branched or unbranched C_1-C_6 alkyl group or branched or unbranched C_2-C_6 alkenyl or alkynyl group;

B2 cont.

wherein R_3 is H, branched or unbranched C_1-C_6 alkyl, branched or unbranched C_2-C_6 alkenyl or alkynyl, C_3-C_7 cycloalkyl, C_3-C_7 cycloalkylalkyl, aryl, heteroaryl, aryl-(C_1-C_6)-alkyl, heteroaryl-(C_1-C_6)-alkyl, substituted C_1-C_6 alkyl, substituted C_3-C_7 cycloalkyl, substituted aryl, substituted heteroaryl, substituted aryl-(C_1-C_6)-alkyl, or substituted heteroaryl-(C_1-C_6)-alkyl, wherein the substituent if present is a halogen, CN, nitro, C_1-C_6 alkyl, OR_{14}, SR_{14}, $N(R_{14})_2$, $SO_2N(R_{14})_2$, CO_2R_{14}, SO_3R_{14}, $N(R_{14})COR_{14}$, $CON(R_{14})_2$, or $N(R_{14})CON(R_{14})_2$;

wherein R_4 is H or CH_3;

wherein R_5 is H, branched or unbranched C_1-C_6 alkyl, branched or unbranched C_2-C_6 alkenyl or alkynyl, C_3-C_7 cycloalkyl, C_3-C_7 cycloalkylalkyl, aryl, heteroaryl, aryl-(C_1-C_6)-alkyl, heteroaryl-(C_1-C_6)-alkyl, substituted C_1-C_6 alkyl, substituted C_3-C_7 cycloalkyl, substituted aryl, substituted heteroaryl, substituted aryl-(C_1-C_6)-alkyl, or substituted heteroaryl-(C_1-C_6)-alkyl, wherein the substituent if present is a halogen, CN, nitro, C_1-C_6 alkyl, OR_{14}, SR_{14}, $N(R_{14})_2$, $SO_2N(R_{14})_2$, CO_2R_{14}, SO_3R_{14}, $N(R_{14})COR_{14}$, $CON(R_{14})_2$, or $N(R_{14})CON(R_{14})_2$;

wherein R_6 is H, branched or unbranched C_1-C_6 alkyl, branched

or unbranched C_2-C_6 alkenyl or alkynyl, C_3-C_7 cycloalkyl, C_3-C_7 cycloalkylalkyl, aryl, heteroaryl, aryl-(C_1-C_6)-alkyl, heteroaryl-(C_1-C_6)-alkyl, substituted C_1-C_6 alkyl, substituted C_3-C_7 cycloalkyl, substituted aryl, substituted heteroaryl, substituted aryl-(C_1-C_6)-alkyl, or substituted heteroaryl-(C_1-C_6)-alkyl, wherein the substituent if present is a halogen, CN, nitro, C_1-C_6 alkyl, OR_{14}, SR_{14}, $N(R_{14})_2$, $SO_2N(R_{14})_2$, CO_2R_{14}, SO_3R_{14}, $N(R_{14})COR_{14}$, $CON(R_{14})_2$, or $N(R_{14})CON(R_{14})_2$;

B2 cancels

wherein R_7 is H, branched or unbranched C_1-C_6 alkyl, branched or unbranched C_2-C_6 alkenyl or alkynyl, C_3-C_7 cycloalkyl, aryl, aryl-(C_1-C_6)-alkyl, CO_2R_{14}, $CON(R_{14})_2$, substituted C_1-C_6 alkyl, substituted aryl, wherein the substituent is $N(R_{14})_2$, halogen, OR_{14} or SR_{14};

wherein R_8 is H or CH_3;

wherein R_{10} is H or F;

wherein R_{11} is H, F, Cl, Br, I, CN, branched or unbranched C_1-C_6 alkyl or alkoxy;

wherein R_{13} is H or F;

and wherein R_{14} is independently H or branched or unbranched C_1-C_6 alkyl. --

---

--14. (Amended) The compound of claim 16, wherein the compound comprises the (+) enantiomer. --

B3

--15. (Amended) The compound of claim 16, wherein the compound comprises the (-) enantiomer.--

--16.(Amended) A compound having the structure:



wherein each m and n is independently an integer from 0 to 2;

wherein each Y and Z is independently



wherein R_1 and R_2 (i) are independently H, branched or unbranched C_1-C_6 alkyl or alkoxy, branched or unbranched C_2-C_6 alkenyl or alkynyl, branched or unbranched C_1-C_6 hydroxyalkyl, hydroxy, substituted or unsubstituted aryl or aryl-(C_1-C_6)-alkyl, or substituted or unsubstituted heteroaryl or heteroaryl-(C_1-C_6)-alkyl, wherein the substituent if present is a halogen, CN, nitro, hydroxy, branched or unbranched C_1-C_6 alkyl or alkoxy group, or branched or unbranched C_2-C_6 alkenyl or alkynyl group; or (ii) taken together form a substituted or unsubstituted cycloalkyl ring containing 3-10 carbons, wherein the substituent if present is a branched or unbranched C_1-C_6 alkyl group or branched or unbranched C_2-C_6 alkenyl or alkynyl group;

wherein R_3 is H, branched or unbranched C_1-C_6 alkyl, branched or unbranched C_2-C_6 alkenyl or alkynyl, C_3-C_7 cycloalkyl, C_3-C_7 cycloalkylalkyl, aryl, heteroaryl, aryl-(C_1-C_6)-alkyl, heteroaryl-(C_1-C_6)-alkyl, substituted C_1-C_6 alkyl, substituted

C_3-C_7 cycloalkyl, substituted aryl, substituted heteroaryl, substituted aryl-(C_1-C_6)-alkyl, or substituted heteroaryl-(C_1-C_6)-alkyl, wherein the substituent if present is a halogen, CN, nitro, C_1-C_6 alkyl, OR_{14}, SR_{14}, $N(R_{14})_2$, $SO_2N(R_{14})_2$, CO_2R_{14}, SO_3R_{14}, $N(R_{14})COR_{14}$, $CON(R_{14})_2$, or $N(R_{14})CON(R_{14})_2$;

wherein R_4 is H or CH_3;

B^3 cont

wherein R_5 is H, branched or unbranched C_1-C_6 alkyl, branched or unbranched C_2-C_6 alkenyl or alkynyl, C_3-C_7 cycloalkyl, C_3-C_7 cycloalkylalkyl, aryl, heteroaryl, aryl-(C_1-C_6)-alkyl, heteroaryl-(C_1-C_6)-alkyl, substituted C_1-C_6 alkyl, substituted C_3-C_7 cycloalkyl, substituted aryl, substituted heteroaryl, substituted aryl-(C_1-C_6)-alkyl, or substituted heteroaryl-(C_1-C_6)-alkyl, wherein the substituent if present is a halogen, CN, nitro, C_1-C_6 alkyl, OR_{14}, SR_{14}, $N(R_{14})_2$, $SO_2N(R_{14})_2$, CO_2R_{14}, SO_3R_{14}, $N(R_{14})COR_{14}$, $CON(R_{14})_2$, or $N(R_{14})CON(R_{14})_2$;

wherein R_6 is H, branched or unbranched C_1-C_6 alkyl, branched or unbranched C_2-C_6 alkenyl or alkynyl, C_3-C_7 cycloalkyl, C_3-C_7 cycloalkylalkyl, aryl, heteroaryl, aryl-(C_1-C_6)-alkyl, heteroaryl-(C_1-C_6)-alkyl, substituted C_1-C_6 alkyl, substituted C_3-C_7 cycloalkyl, substituted aryl, substituted heteroaryl, substituted aryl-(C_1-C_6)-alkyl, or substituted heteroaryl-(C_1-C_6)-alkyl, wherein the substituent if present is a halogen, CN, nitro, C_1-C_6 alkyl, OR_{14}, SR_{14}, $N(R_{14})_2$, $SO_2N(R_{14})_2$, CO_2R_{14}, SO_3R_{14}, $N(R_{14})COR_{14}$, $CON(R_{14})_2$, or $N(R_{14})CON(R_{14})_2$;

wherein R_7 is H, branched or unbranched C_1-C_6 alkyl, branched or unbranched C_2-C_6 alkenyl or alkynyl, C_3-C_7 cycloalkyl, aryl, aryl-(C_1-C_6)-alkyl, CO_2R_{14}, $CON(R_{14})_2$, substituted C_1-C_6 alkyl, substituted aryl, wherein the substituent is $N(R_{14})_2$, halogen, OR_{14} or SR_{14};

wherein R_8 is H or CH_3;

wherein R_{10} is H or F;

B3 concld

wherein R_{11} is H, F, Cl, Br, I, CN, branched or unbranched C_1-C_6 alkyl or alkoxy;

wherein R_{13} is H or F;

and wherein R_{14} is independently H or branched or unbranched C_1-C_6 alkyl. --

B4

--22. (Amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 16 and a pharmaceutically acceptable carrier.--

B5

--29. (Amended) A pharmaceutical composition obtained by combining a therapeutically effective amount of the compound of claim 16 and a pharmaceutically acceptable carrier. --

--30. (Amended) A process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of claim 16 and a pharmaceutically acceptable carrier. --

B6

--32. (Amended) A method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human α_{1d} adrenergic receptor which comprises administering to the subject an amount of the compound of claim 16 effective to treat the disease. --

--33. (Amended) A method of treating a subject afflicted with

hypertension which comprises administering to the subject an amount of the compound of claim 16 effective to treat the disease. --

B4 cancel

--34. (Amended) A method of treating a subject afflicted with Raynaud's disease which comprises administering to the subject an amount of the compound of claim 16 effective to treat the disease. --

B7

--36. (Amended) A method of treating a subject afflicted with urinary incontinence which comprises administering to the subject an amount of the compound of claim 16 effective to treat the disease. -

A marked-up copy of the amendments to the claims is attached hereto as **Exhibit A**.

REMARKS

Claims 1-42 were pending in the subject application. By this Amendment, applicants have canceled claims 1, 5, 6 and 13, and have amended claims 2, 7, 14-16, 22, 29-30, 32-34, and 36. Accordingly, upon entry of this Amendment, claims 2-4, 7-12, and 14-42, as amended, will be pending and presently under examination.

Applicants maintain that the amendments to claims 2, 7, 14-16, 22, 29-30, 32-34, and 36 do not raise any issue of new matter. Support for amended claim 2 may be found inter alia in the specification, as originally filed, on page 15, lines 14-23. Support for amended claim 7 may be found inter alia in the specification, as originally filed, on page 16, line 3 through page 18, line 20. Support for amended claims 14 and 15 may be